Waters (WAT)
(Delayed Data from NYSE)
$336.49 USD
-2.34 (-0.69%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $336.64 +0.15 (0.04%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
WAT 336.49 -2.34(-0.69%)
Will WAT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for WAT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for WAT
Deciphering Waters (WAT) International Revenue Trends
Waters (WAT) Q2 Earnings & Sales Beat Estimates, Fall Y/Y
WAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, Waters (WAT) Q2 Earnings: A Look at Key Metrics
Waters (WAT) Q2 Earnings and Revenues Top Estimates
Sensus Healthcare, Inc. (SRTS) Earnings Expected to Grow: Should You Buy?
Other News for WAT
Waters Corporation Appoints Heather Knight to Board of Directors
Waters Corp.: Embedded Expectations High Under Present Conditions
Waters Corporation Welcomes New Board Member Heather Knight
Waters Corporation (WAT): Hold Rating Affirmed Amid Balanced Outlook and Market Dynamics
Analysts Have Conflicting Sentiments on These Healthcare Companies: United Therapeutics (UTHR), Waters (WAT) and Regeneron (REGN)